Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
종목 코드 BFRI
회사 이름Biofrontera Inc
상장일Oct 14, 2021
CEOLuebbert (Hermann)
직원 수92
유형Ordinary Share
회계 연도 종료Oct 14
주소120 Presidential Way,
도시WOBURN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호01801
전화17812451325
웹사이트https://www.biofrontera-us.com/
종목 코드 BFRI
상장일Oct 14, 2021
CEOLuebbert (Hermann)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음